Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $460000.0.

  • C4 Therapeutics' Depreciation & Amortization (CF) rose 407.24% to $460000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 1374.43%. This contributed to the annual value of $1.8 million for FY2024, which is 329.79% down from last year.
  • C4 Therapeutics' Depreciation & Amortization (CF) amounted to $460000.0 in Q3 2025, which was up 407.24% from $615000.0 recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Depreciation & Amortization (CF) registered a high of $615000.0 during Q2 2025, and its lowest value of $305000.0 during Q1 2022.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $448000.0 (2024), whereas its average is $441947.4.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 3237.25% in 2022, then soared by 7868.85% in 2023.
  • Over the past 5 years, C4 Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $323000.0 in 2021, then skyrocketed by 61.3% to $521000.0 in 2022, then decreased by 17.47% to $430000.0 in 2023, then rose by 11.63% to $480000.0 in 2024, then dropped by 4.17% to $460000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $460000.0 for Q3 2025, versus $615000.0 for Q2 2025 and $456000.0 for Q1 2025.